LBI-HTA - Publications - Search - Plerixafor (Mozobil ®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma

Hintringer, K. (2010): Plerixafor (Mozobil ®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma. DSD: Horizon Scanning in Oncology 08.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
262Kb
Abstract

Patients suffering from hematological malignancies such as Non Hodgkin’s Lymphoma, Hodgkin Lymphoma or Multiple Myeloma are eligible for high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). Despite a range of options for collecting sufficient numbers of HSC for transplantation, approximately 10-30% of patients eligible for HSCT are not able to collect the minimum target cell count. These patients are considered to be poor mobilizers. The novel agent plerixafor, is expected to improve the mobilization of HSC into the peripheral blood when added to standard treatment in order to provide poor mobilizers with access to HSCTand hight-dose chemotherapy.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:Plerixafor, mozobil, autologous hematopoietic stem cell transplantation, lymphoma,multiple myeloma
Subjects:QZ Pathology > QZ 200-380 Neoplasms.Cysts
WH Hemic and lymphatic systems
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:DSD: Horizon Scanning in Oncology 08
Deposited on:21 Apr 2010 13:56
Last Modified:21 Apr 2010 13:56

Repository Staff Only: item control page